| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ahmed M Abdelfattah, Sally A Abuelezz, Nevien Hendawy, Eman A Negm, Salwa Abd El Khalek Nawishy, Ahmed Mohamed Mohamed Khali. Sonic hedgehog pathway as a new target of atypical antipsychotics: Revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. Life sciences. 2023-01-17. PMID:36649751. |
in this study, effects of the anti-psychotics amisulpride and/or aripiprazole on the shh-pathway and its relation to cognitive functions and neurogenesis in a rat model of schizophrenia were tested. |
2023-01-17 |
2023-08-14 |
rat |
| Alessandro Cuomo, Eugenio Aguglia, Stefano Biagini, Alessandro Carano, Massimo Clerici, Armando D'Agostino, Sergio De Filippis, Serafino De Giorgi, Arianna Goracci, Claudia Libri, Francesco Lombardi, Matteo Lupi, Giuseppe Maina, Giovanni Martinotti, Pietro Nigro, Mauro Pettorruso, Valerio Ricci, Eros Rossi, Felicia Russo, Andrea Fagiolin. Two-Injection Start Regimen of Long-Acting Aripiprazole in 133 Patients With Schizophrenia. Journal of clinical psychopharmacology. vol 43. issue 1. 2022-12-30. PMID:36584247. |
two-injection start regimen of long-acting aripiprazole in 133 patients with schizophrenia. |
2022-12-30 |
2023-08-14 |
Not clear |
| I Yu Dorozheno. [Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 122. issue 12. 2022-12-20. PMID:36537633. |
[modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)]. |
2022-12-20 |
2023-08-14 |
Not clear |
| I Yu Dorozheno. [Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 122. issue 12. 2022-12-20. PMID:36537633. |
according to numerous studies, aripiprazole, due to its unique pharmacological profile and combination of clinical factors, is the drug of first choice for anti-relapse supportive therapy of schizophrenia. |
2022-12-20 |
2023-08-14 |
Not clear |
| Zhizhong Xu, Chunyan Wen, Yinghua Huang, Qianfa Yuan, Xianhua Zhang, Duoduo Lin, Liangsheng Liu, Wenqiang Wan. Effects of Glycogen Synthase Kinase-3 Beta Gene Polymorphisms on the Plasma Concentration of Aripiprazole in Chinese Patients with Schizophrenia: A Preliminary Study. Journal of molecular neuroscience : MN. 2022-12-20. PMID:36539584. |
effects of glycogen synthase kinase-3 beta gene polymorphisms on the plasma concentration of aripiprazole in chinese patients with schizophrenia: a preliminary study. |
2022-12-20 |
2023-08-14 |
Not clear |
| Zhizhong Xu, Chunyan Wen, Yinghua Huang, Qianfa Yuan, Xianhua Zhang, Duoduo Lin, Liangsheng Liu, Wenqiang Wan. Effects of Glycogen Synthase Kinase-3 Beta Gene Polymorphisms on the Plasma Concentration of Aripiprazole in Chinese Patients with Schizophrenia: A Preliminary Study. Journal of molecular neuroscience : MN. 2022-12-20. PMID:36539584. |
this study explored the differences in glycogen synthase kinase-3 beta (gsk3β) gene polymorphisms between patients with schizophrenia and healthy controls and investigated the association between gene polymorphisms and plasma concentration of aripiprazole. |
2022-12-20 |
2023-08-14 |
Not clear |
| Howard C Margolese, Matthieu Boucher, Francois Therrien, Guerline Clerziu. Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the ReLiAM study. BMC psychiatry. vol 22. issue 1. 2022-12-09. PMID:36482352. |
treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the reliam study. |
2022-12-09 |
2023-08-14 |
Not clear |
| Howard C Margolese, Matthieu Boucher, Francois Therrien, Guerline Clerziu. Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the ReLiAM study. BMC psychiatry. vol 22. issue 1. 2022-12-09. PMID:36482352. |
reliam, real-life assessment of abilify maintena, was the first reported long-term prospective non-interventional study for patients with schizophrenia treated with aripiprazole once-monthly injectable formulation (aom) under real-life conditions. |
2022-12-09 |
2023-08-14 |
Not clear |
| Karl Josef Föhr, Michael Rapp, Michael Fauler, Thomas Zimmer, Bettina Jungwirth, David Alexander Christian Messere. Block of Voltage-Gated Sodium Channels by Aripiprazole in a State-Dependent Manner. International journal of molecular sciences. vol 23. issue 21. 2022-11-11. PMID:36361681. |
aripiprazole is an atypical antipsychotic drug, which is prescribed for many psychiatric diseases such as schizophrenia and mania in bipolar disorder. |
2022-11-11 |
2023-08-14 |
Not clear |
| Lin-Fei Chen, Ying Chen, You-Yu Duan, Man-Man Zhang, Pei-Yao Xu, Ranjith Kumar Kankala, Shi-Bin Wang, Ai-Zheng Che. Preparation of aripiprazole-poly(methyl vinyl ether- Regenerative biomaterials. vol 9. 2022-11-04. PMID:36330352. |
preparation of aripiprazole-poly(methyl vinyl ether- aripiprazole (ari), a second-generation atypical antipsychotic drug approved for schizophrenia treatment, shows good efficacy against depression. |
2022-11-04 |
2023-08-14 |
Not clear |
| Yasemin Eldemir Okay, İbrahim Halil Kenger, Hamit Yildiz, Mehmet Tahir Hüsunet, Lale Dönbak, Ahmet Kayraldi. Drug and chemical toxicology. 2022-10-24. PMID:36278274. |
in line with these results, it was observed that the use of aripiprazole in the treatment of schizophrenia did not pose any acute genotoxic and cytotoxic risk. |
2022-10-24 |
2023-08-14 |
human |
| Xenia M Hart, Christoph Hiemke, Luzie Eichentopf, Xenija M Lense, Hans Willi Clement, Andreas Conca, Frank Faltraco, Vincenzo Florio, Jessica Grüner, Ursula Havemann-Reinecke, Espen Molden, Michael Paulzen, Georgios Schoretsanitis, Thomas G Riemer, Gerhard Gründe. Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis. Psychopharmacology. 2022-10-04. PMID:36195732. |
therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis. |
2022-10-04 |
2023-08-14 |
Not clear |
| Jolanta Orzelska-Górka, Joanna Mikulska, Anna Wiszniewska, Grażyna Biał. New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. International journal of molecular sciences. vol 23. issue 18. 2022-09-23. PMID:36142523. |
the purpose of this review presents the background and evidence for the use of the new second/third-generation antipsychotics (aripiprazole, cariprazine, lurasidone, asenapine, brexpiprazole, lumateperone, pimavanserin) in treatment of schizophrenia and depression. |
2022-09-23 |
2023-08-14 |
Not clear |
| Amber N Edinoff, Hamza Mohammad-Amin, Amira S Odish. Silent Neuroleptic Malignant Syndrome: A Case Report of Atypical Antipsychotic Induced Elevation of Creatinine Kinase and Altered Mental Status. Health psychology research. vol 10. issue 3. 2022-08-24. PMID:35999974. |
34-year-old african american male with a diagnosis of schizophrenia was placed on aripiprazole and risperidone for psychosis and mood stabilization. |
2022-08-24 |
2023-08-14 |
Not clear |
| Jeffrey M Cochran, Hui Fang, John G Sonnenberg, Elan A Cohen, Jean-Pierre Lindenmayer, J Corey Reuteman-Fowle. Healthcare Provider Engagement with a Novel Dashboard for Tracking Medication Ingestion: Impact on Treatment Decisions and Clinical Assessments for Adults with Schizophrenia. Neuropsychiatric disease and treatment. vol 18. 2022-08-05. PMID:35928793. |
a phase 3b open-label clinical trial used aripiprazole tablets with sensor (as; includes pills with ingestible event-marker, wearable sensor patches and smartphone application) in adults with schizophrenia. |
2022-08-05 |
2023-08-14 |
Not clear |
| Yun Tien, Hsiang-Ping Huang, Ding-Lieh Liao, Shang-Chien Huan. Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan. Therapeutic advances in psychopharmacology. vol 12. 2022-08-04. PMID:35923249. |
dose-response analysis of aripiprazole in patients with schizophrenia in taiwan. |
2022-08-04 |
2023-08-14 |
Not clear |
| Yun Tien, Hsiang-Ping Huang, Ding-Lieh Liao, Shang-Chien Huan. Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan. Therapeutic advances in psychopharmacology. vol 12. 2022-08-04. PMID:35923249. |
patients with schizophrenia from tungs' taichung metroharbor hospital in central taiwan were recruited to analyze the dose-response relationship of aripiprazole in the chinese population. |
2022-08-04 |
2023-08-14 |
Not clear |
| Jeffrey M Cochran, Hui Fang, Christophe Le Gallo, Timothy Peters-Strickland, Jean-Pierre Lindenmayer, J Corey Reuteman-Fowle. Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia. Patient preference and adherence. vol 16. 2022-08-04. PMID:35923658. |
participant engagement and symptom improvement: aripiprazole tablets with sensor for the treatment of schizophrenia. |
2022-08-04 |
2023-08-14 |
human |
| Jeffrey M Cochran, Hui Fang, Christophe Le Gallo, Timothy Peters-Strickland, Jean-Pierre Lindenmayer, J Corey Reuteman-Fowle. Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia. Patient preference and adherence. vol 16. 2022-08-04. PMID:35923658. |
a recent, phase 3b, mirror-image clinical trial of outpatients with schizophrenia found that use of aripiprazole tablets with sensor (as; abilify mycite |
2022-08-04 |
2023-08-14 |
human |
| Dalia A Nawwar, Hala F Zaki, Rabab H Saye. Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats. Inflammopharmacology. 2022-07-25. PMID:35876932. |
this study investigates the effects of aripiprazole and sertindole on the nrg1/erbb4 and pi3k/akt/mtor signaling pathways in ketamine-induced schizophrenia in rats. |
2022-07-25 |
2023-08-14 |
rat |